A CVS deal favoring Novo Nordisk’s Wegovy over other obesity drugs has raised concerns among patients who may be forced to switch medications. This decision could impact those currently using alternative treatments like Zepbound. Despite CVS’s move, analysts suggest it won’t significantly affect Eli Lilly’s dominance in the obesity drug market. The deal highlights the competitive landscape in pharmaceuticals where coverage decisions can directly affect patient care.
— new from The New York Times